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Perspectives
The lack of a “gold standard” deﬁ nition for severe malaria has been a longstanding problem 
for both clinicians and researchers. 
The deﬁ nitions currently used 
comprise a set of clinical and laboratory 
parameters associated with an increased 
risk of death [1,2], combined with 
the presence of Plasmodium falciparum 
parasitemia [2,3]. In young children, 
these criteria are predominantly altered 
consciousness, severe anemia, and 
respiratory distress [1,3]; a broader 
range of criteria is applicable to 
adolescents and adults [2]. 
While these criteria are sensitive in 
diagnosing severe malaria, they are 
also present in other serious illnesses. 
Since asymptomatic parasitemia is 
common in malaria-endemic areas, 
patients fulﬁ lling current World 
Health Organization (WHO) criteria 
for severe malaria [3] often have 
disease attributable to another cause, 
such as bacterial sepsis with incidental 
parasitemia [4], thereby limiting the 
speciﬁ city of this deﬁ nition.
For a treating clinician, a sensitive 
but less speciﬁ c deﬁ nition of severe 
malaria is entirely appropriate. 
However, for research purposes, a 
sensitive clinical deﬁ nition may not 
necessarily be appropriate, and the 
case deﬁ nition should depend on the 
research question. 
For example, in a recent randomized 
controlled trial of quinine versus 
artesunate for severe malaria [5], the 
aim was to compare the efﬁ cacy of 
two drugs in real-world resource-poor 
clinical settings. The primary endpoint, 
mortality, included all patients enrolled 
with a bedside clinical diagnosis of 
severe malaria, who were positive for 
P. falciparum by a rapid diagnostic 
test. This sensitive but less speciﬁ c 
deﬁ nition had clinical applicability, 
but necessitated a large sample size to 
overcome the loss of power from the 
inclusion of patients with less severe 
disease or severe illness unrelated to 
malaria. 
At the other end of the 
spectrum, studies of severe malaria 
pathophysiology require deﬁ nitions 
with much higher speciﬁ city to ensure 
accurate identiﬁ cation of mechanisms 
of disease; sensitivity is less important 
in these situations. Such speciﬁ city in 
severe malaria has been improved using 
extended laboratory criteria, lumbar 
puncture, indirect ophthalmoscopy 
[6], autopsy validation [7], and a high 
parasite density threshold [2,8].
Deﬁ ning Severe Malaria Cases in 
Community Intervention Studies
What deﬁ nition for severe malaria 
should be used when severe malaria 
is a study endpoint rather than an 
entry criterion? In vaccine trials or 
intervention studies designed to 
prevent severe disease, case deﬁ nitions 
should reﬂ ect a balance between 
sensitivity and speciﬁ city. Neither of 
the deﬁ nitions described above would 
be optimal. Ideally, a level of speciﬁ city 
would be adopted that ensures an 
accurate estimate of vaccine efﬁ cacy, 
without reducing the sensitivity to a 
level that requires a major increase in 
the sample size. 
In this issue of PLoS Medicine, Philip 
Bejon et al. present an important study 
in which they adopt a new approach to 
balancing the sensitivity and speciﬁ city 
of criteria for severe malaria [9]. The 
authors deﬁ ne malaria attributable 
fractions (MAFs) [10] for different case 
deﬁ nitions of severe malaria in children 
in Kenya, which estimate the positive 
predictive value for severe malaria 
for a given background prevalence 
of asymptomatic parasitemia, i.e., 
the proportion of severe disease with 
parasitemia that is attributable to 
malaria. 
Using a sample of 4,583 community-
based children with asymptomatic 
parasitemia and 1,422 hospitalized 
children with signs of severe malaria, 
the risk of severe disease was modeled 
using logistic regression with varying 
parasite densities and a range of 
comorbidities that may have altered the 
speciﬁ city of their deﬁ nition of severe 
malaria. In their coastal Kenyan setting, 
they calculated that an overall MAF of 
95% could be achieved by applying a 
threshold parasitemia of more than 
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Linked Research Article 
This Perspective discusses the 
following new study published in PLoS 
Medicine:
Bejon P, Berkley JA, Mwangi T, Ogada 
E, Mwangi I, et al. (2007) Deﬁ ning 
childhood severe falciparum malaria for 
intervention studies. PLoS Med 4: e251. 
doi:10.1371/journal.pmed.0040251
The accepted deﬁ nition of severe 
malaria is appropriate for clinical 
purposes, but Philip Bejon and 
colleagues show that its speciﬁ city 
in clinical trials may be improved by 
applying a parasite density threshold 
and by excluding children with certain 
conditions.
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2,500 parasites/µl after excluding 
children with meningitis, clinician-
diagnosed lower respiratory infection, 
bacteremia, and gastroenteritis with 
severe dehydration. 
The authors’ rigorous analysis 
shows what can be achieved with large 
datasets derived from meticulous 
prospective collection of clinical and 
laboratory information. The study 
included data on asymptomatic 
parasitemia from settings with different 
transmission intensity. The researchers 
were able to collect blood cultures 
from all hospitalized children, and HIV 
status was available for almost all. 
Despite the strengths of the study, 
there are some limitations. The absence 
of indirect ophthalmoscopy [6] 
(although this is not a widely available 
procedure) and of cerebrospinal ﬂ uid 
examination in 22% of children with 
signs of cerebral malaria may have 
reduced the positive predictive values 
of their deﬁ nition. A MAF of 32% for 
children with high parasitemia and 
conﬁ rmed meningitis could imply 
a contributory role of malaria to 
meningitis, and vice versa, but could 
also indicate some inaccuracy of the 
MAF in estimating the true burden of 
severe malaria.
Given the high prevalence of HIV 
infection in African children and known 
malaria–HIV interactions, a signiﬁ cant 
ﬁ nding was that HIV and malnutrition 
did not reduce the MAF, leading the 
authors to recommend that such patients 
should not be excluded from the case 
deﬁ nition. Interestingly, the MAF for 
respiratory distress deﬁ ned by deep 
breathing [1] was the same as that for 
the potentially more objective measure 
of raised respiratory rate. Other notable 
ﬁ ndings included the high predictive 
value for severe malaria of gram-negative 
bacteremia (plausibly secondary to 
malaria) and low positive predictive value 
for gram-positive bacteremia (plausibly 
incidental to malaria). 
Clinical Implications and Future 
Research
Bejon et al. have now demonstrated 
the utility of such methodology in 
identifying a case deﬁ nition that 
appropriately balances sensitivity 
and speciﬁ city for severe malaria 
in coastal Kenya. Their deﬁ nition 
provides a rational endpoint for future 
vaccine trials and other community-
based malaria prevention trials at 
this site. The authors acknowledge 
that these ﬁ ndings are applicable to 
coastal Kenya and cannot necessarily 
be generalized to other settings. 
Nevertheless, the approach they have 
used will pave the way for others to 
derive locally applicable MAFs and test 
the generalizability of their ﬁ ndings. 
Indeed the derivation of MAFs should, 
where possible, become an intrinsic 
part of the planning of vaccine/
intervention trials and epidemiology 
studies of severe malaria. 
In areas of high malaria transmission, 
the parasitemic thresholds for 
deﬁ ning severe disease will increase. 
Interestingly, in Kiliﬁ , the thresholds 
deﬁ ning uncomplicated and severe 
malaria were similar. If conﬁ rmed 
elsewhere, this raises the possibility that 
when parasite density thresholds are 
available for uncomplicated malaria 
[10] but not for severe disease, the 
former could potentially be applied to 
the latter. 
Recent studies suggest that 30% 
of falciparum malaria occurs outside 
Africa, mostly in South and Southeast 
Asia [11], and often in areas with 
lower, unstable transmission where 
severe disease occurs in adults as well as 
children. Calculation of MAFs will be 
required for each of these age groups. 
In these regions P. vivax may account 
for more than 50% of infections and 
is a likely cause of a signiﬁ cant yet 
neglected burden of severe disease, 
particularly severe anemia in children 
[12]. A similar approach to deﬁ ning 
attributable fractions for P. vivax 
infections as that demonstrated 
for P. falciparum will allow a better 
appreciation of the relative burden 
of P. vivax and other malaria species 
whose association with severe morbidity 
is often dismissed [12]. 
Finally, while the lengthy 
descriptions of severe malaria included 
in current WHO guidelines [3] are 
appropriate for clinical purposes, they 
lack clarity for research purposes. This 
is particularly true for case deﬁ nitions 
in adults, resulting in the frequent use 
of “modiﬁ ed WHO criteria” to deﬁ ne 
severe malaria in published studies 
[2,5,13]. A parasite threshold to 
improve speciﬁ city in severe anemia 
was deﬁ ned for research purposes in 
the 1990 WHO guidelines [8], but 
was dropped from the current WHO 
guidelines [3]. Forthcoming guidelines 
should more clearly and concisely 
establish case deﬁ nitions for severe 
malaria in both children and adults, 
suitable for different research purposes 
in different epidemiological settings. 
For malaria prevention trials and 
disease burden studies, forthcoming 
WHO guidelines should highlight the 
utility of Bejon et al.’s MAF approach 
in developing locally applicable case 
deﬁ nitions of severe malaria.  
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